Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDH.L Regulatory News (IDH)

  • There is currently no data for IDH

Directorate Change

14 Dec 2012 07:00

RNS Number : 5188T
Immunodiagnostic Systems Hldgs PLC
14 December 2012
 



14 December 2012

 

Immunodiagnostic Systems Holdings plc

 

Chris Yates appointed as Group Finance Director

 

 

Immunodiagnostic Systems Holdings plc ("IDS"), a leading producer of manual and automated specialist diagnostic testing kits and instrumentation for the clinical and research markets, today announces that Chris Yates has been appointed Group Finance Director, with effect from 4th March 2013. 

 

Chris Yates, aged 38, joins IDS from private equity backed Nexus Vehicle Holdings Limited, where he has acted as Group Finance Director since January 2009. During his time at Nexus, as well as holding overall responsibility for finance and human resources, Chris oversaw the acquisition of Adapted Vehicle Hire Limited in May 2010.

 

From 2005 to 2007, Chris held the position of Group Finance Director at Cozart plc, allowing him to gain significant experience in the medical diagnostics industry.  During his time at Cozart, Chris led the acquisitions of four European companies: Spinreact SA (Spain), HL Scandinavia (Sweden), Nemesis Scientific Limited (UK) and Medib Skandinavien AB (Sweden) creating a pan-European medical diagnostics group. Cozart was subsequently acquired by Concateno plc (now part of Alere Inc.) in October 2007 for £64m in cash.

 

In 2008 Chris then furthered his industry expertise by acting as Co-founder and Finance Director of private specialist diagnostics company, Abingdon Health Limited.

 

From 4th March 2013 Barry Hextall, currently interim Group Finance Director, will resume his previous role as Deputy Group Finance Director.

 

Patrik Dahlen, Chief Executive Officer of IDS, commented: "It is a pleasure to announce that Chris Yates will be joining our team as Group Finance Director. As well as having a strong financial background, I am confident that Chris's knowledge and experience in the diagnostics industry will prove to be invaluable to IDS during this crucial time in the evolution of the business as a leading innovator and provider of specialist assays and diagnostic testing kits.

 

"I would also like to thank Barry Hextall for his continued support as Interim Finance Director."

 

For further information:

 

Immunodiagnostic Systems Holdings plc

Tel : +44 (0)191 519 0660

Patrik Dahlen, Chief Executive Officer

 

 

 

 

 

Peel Hunt LLP

Tel : +44 (0)207 418 8900

James Steel

 

Dr Vijay Barathan

 

 

 

FTI Consulting

Tel : +44 (0)207 831 3113

Ben Atwell

 

Simon Conway

 

Mo Noonan

 

 

 

Additional Information

Christopher Henry Francis Yates (aged 38) currently holds and has held (including all appointments during the five years preceding the date of this announcement), the following directorships and partnerships, other than the Company:

 

Current directorships:

Adapted Vehicle Hire Limited

Forsite Diagnostics Limited

Nexus VRM Limited

Nexus Vehicle Management Ltd

Nexus Vehicle Holdings Limited

Abingdon Health LTD

 

Chris currently has no shares in the Company and there are no other disclosures required pursuant to Rule 17 and Schedule 2; paragraph (g) of the AIM Rules for Companies.

 

About Immunodiagnostic Systems Holdings PLC

The Group operates in the in-vitro diagnostics ("IVD") market by designing, manufacturing and selling immunoassay kits as well as its automated analyser, the IDS-iSYS System. The IDS product range is used to measure or detect particular substances within a sample, thus aiding the diagnosis or monitoring of a disease or providing information for research studies.

 

http://www.idsplc.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAGGGQGPUPPPWW
Date   Source Headline
14th Dec 20127:00 amRNSDirectorate Change
12th Dec 20124:00 pmRNSHolding(s) in Company
12th Dec 20127:00 amRNSHolding(s) in Company
10th Dec 20126:08 pmRNSHolding(s) in Company
30th Nov 20126:15 pmRNSDirector/PDMR Shareholding
26th Nov 20127:00 amRNSHalf Yearly Report
24th Oct 201210:59 amRNSNotice of Results
19th Oct 20127:00 amRNSDirectorate Change Update
17th Oct 201211:41 amRNSSettlement on Escalon debt
1st Oct 201210:31 amRNSHolding(s) in Company
17th Sep 201212:54 pmRNSRedirectorate
14th Sep 20126:09 pmRNSAGM Result
14th Sep 20127:00 amRNSAGM Statement
15th Aug 20127:00 amRNSBoard Change
3rd Aug 20122:33 pmRNSDirector/PDMR Shareholding
30th Jul 201210:18 amRNSHolding(s) in Company
27th Jul 20129:29 amRNSHolding(s) in Company
27th Jul 20129:24 amRNSHolding(s) in Company
26th Jul 201210:30 amRNSAnnual Report and Accounts & Notice of AGM
2nd Jul 20127:00 amRNSDirectorate Change
25th Jun 20127:00 amRNSFinal Results
14th Jun 20127:00 amRNSProduct Launch
23rd Apr 201211:02 amRNSIDS Receives Prestigious Queens Award
12th Apr 20127:00 amRNSTrading Statement
4th Apr 20129:56 amRNSHolding(s) in Company
4th Apr 20127:00 amRNS1,25-Dihydroxy Vitamin D Assay Launch
14th Feb 20127:00 amRNSFDA clearance for a new specialist assay
9th Feb 20127:00 amRNSChange of Adviser
1st Feb 20123:16 pmRNSChange of Adviser
30th Jan 20128:27 amRNSDirector/PDMR Shareholding - Replacement
30th Jan 20127:00 amRNSDirector/PDMR Shareholding
30th Jan 20127:00 amRNSDirector/PDMR Shareholding
27th Jan 20127:00 amRNSDirector/PDMR Shareholding
24th Jan 20123:18 pmRNSHolding(s) in Company
24th Jan 20122:38 pmRNSHolding(s) in Company
23rd Jan 20127:01 amRNSTrading update
12th Jan 201212:13 pmRNSHolding(s) in Company
15th Dec 201111:02 amRNSHolding(s) in Company
30th Nov 20115:23 pmRNSTotal Voting Rights
28th Nov 20117:00 amRNSInterim Results
14th Nov 20112:03 pmRNSIssue of Equity
6th Oct 20117:00 amRNSTrading Update
4th Oct 20112:45 pmRNSHolding(s) in Company
8th Sep 20115:22 pmRNSResult of AGM
8th Sep 20117:00 amRNSAGM Statement
31st Aug 20114:35 pmRNSPrice Monitoring Extension
30th Aug 20117:00 amRNSDirectorate Change
25th Jul 20117:00 amRNSDirectorate Change
29th Jun 20114:50 pmRNSExercise of Options & Total Voting Rights
27th Jun 20117:00 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.